

# Cardiometabolic diseases

Clinical trial of a new compound that is being developed for the treatment of cardiometabolic diseases






## Compensation

-  **€ 1,692** + € 0.23 per km travel allowance
- If you go home early as a reserve participant, you will also receive compensation
  - You will receive the compensation and your travel expenses within 21 days after the follow-up visit




## Medication administration

-  4 to 14 times a capsule

## Target audience

-  Male or female
-  Healthy
-  18 to 55 years
-  At least 50 kg
-  BMI between 18.5 and 29.9 kg/m²
-  At most 1 cigarette per day


## Time investment


-  Medical screening (1 time)
-  Stay: 1 time 6 days
-  Follow-up visit (1 time)

## Particularities

-  No particularities

## Criteria


- 

**Criteria for females**  
*(you meet at least one criterion)*  
Passed the menopause,  
Sterilized
- 


**Criteria for males**  
There are no contraceptive criteria for males

- 

**Ethnicity**  
n/a



## Schedule



ICON scores 8,2/10  674 reviews  
90% of the participants recommend ICON

 feedback company

“Very pleasant and friendly staff made my 28 day stay very comfortable.”

John Patrick

25-02-2025

“All was arranged well. Questions get answered quickly on the spot. Friendly staff and the food is great.”

Ellen


26-04-2023

“It makes me feel good, to know that I contributed to something important.”

Astrid

12-04-2023

“I always enjoy staying at ICON for a while.”

CE

14-02-2025

This research overview was created on 17-04-2025. We strive to keep our overviews up to date, but it is possible that the latest changes have not been incorporated into this overview. For the most current data, please refer to our website.